INTRODUCTION
============

Gastroesophageal reflux disease (GERD), which includes reflux esophagitis, is a disease during which stomach contents (mainly acid and pepsin) are refluxed into the esophagus, resulting in various clinical symptoms and mucosal changes. Reflux esophagitis is a chronic condition characterized by severe lesions caused by prolonged exposure to acid. In general, strong acidic gastric juice stimulates the esophagus to induce refluxing accompanied by a burning sensation from the chest to the throat, leading to chest tightness, breathing difficulty, and, in severe cases, heartburn. Frequent coughing and reflux secretions lead to bitter tastes in the mouth from which aspiration pneumonia may develop as a complication ([@b23-pnfs-24-159]; [@b18-pnfs-24-159]).

The main cause of reflux esophagitis is eating habits. Intakes too high in fatty, fried, or spicy food can increase gastric acid secretion, while overeating and rapid food intake increase gastrointestinal pressure which makes it difficult to neutralize stomach acid. Another cause of reflux esophagitis is the habit of lying down straight after meals. Lying down after overeating is often linked to reflux esophagitis. Moreover, cigarettes, caffeine, soft drinks, chocolate, peppermint, and orange juice can weaken the squeezing ability of the sphincter, causing reflux esophagitis ([@b3-pnfs-24-159]; [@b5-pnfs-24-159]; [@b4-pnfs-24-159]). The most commonly used drugs for treatment of reflux esophagitis are proton pump inhibitors and histamine H~2~ receptor (H~2~R) blockers. These drugs lower the acidity of gastric juice and reduce irritations when gastric reflux occurs ([@b25-pnfs-24-159]; [@b1-pnfs-24-159]).

The genes encoding four histamine receptor subtypes (H~1~, H~2~, H~3~, and H~4~) have been cloned, and the receptors and their downstream signaling pathways have been pharmacologically characterized ([@b22-pnfs-24-159]). H~2~R is a G protein-coupled receptor that couples with adenylyl cyclase, which produces the intracellular second messenger cyclic adenosine monophosphate (cAMP) ([@b12-pnfs-24-159]; [@b13-pnfs-24-159]). In general, H~2~R is present in gastric parietal cells and regulates secretion signals in the stomach. Activation of H~2~R in gastric parietal cells increases production of cAMP and induces release of hydrogen ions (H^+^) in the gastric juice by proton pump, leading to increased gastric juice acidity. Therefore, H~2~R blockers may be useful for treating diseases that involve gastric acid hypersecretion, such as gastric ulcers and reflux esophagitis ([@b15-pnfs-24-159]; [@b20-pnfs-24-159]; [@b26-pnfs-24-159]).

*Cudrania tricuspidata* is a deciduous tree that has been used in traditional medicine to treat eczema, mumps, pulmonary tuberculosis, allergy, and acute arthritis ([@b27-pnfs-24-159]). It has been reported that different parts of the tree (fruit, root, stem, and leaf) may exert beneficial antiinflammatory, anti-obesity, and antioxidant effects ([@b21-pnfs-24-159]; [@b16-pnfs-24-159]; [@b10-pnfs-24-159]; [@b6-pnfs-24-159]). Although there is increasing evidence for the different physiological activities induced by *C. tricuspidata*, the molecular mechanisms of action of *C. tricuspidata* on GERD and reflux esophagitis have not yet been elucidated.

In the present study, we used the U937 monocyte cell line and pylorus-ligated rat models to evaluate the potential activity of *C. tricuspidata* as an H~2~R antagonist and reflux esophagitis agent. The aim of this study is to provide evidence that ethanol extracts of *C. tricuspidata* leaves negatively regulate H~2~R activity and apparently act as specific and competitive H~2~R antagonists in terms of the secretion blockage of gastric acid similar to that of ranitidine.

MATERIALS AND METHODS
=====================

Preparation of *C. tricuspidata* extract
----------------------------------------

Dried *C. tricuspidata* leaves were pulverized to an appropriate size and placed in an extraction vessel. Ethanol (0% to 70%, corresponding to 10 times the weight of the leaves) was added to the extraction vessel, refluxed, and stirred at 50°C for 6 h. *C. tricuspidata* extracts were adsorbed and filtered by perlite to remove insoluble impurities. The filtered juice extract was concentrated using a rotary vacuum evaporator (EYELA, Tokyo, Japan), lyophilized, pulverized, and powdered. The dried materials were resuspended in 0.5% methyl cellulose (MC) for animal experiments and in dimethyl sulfoxide (DMSO) for cellular experiments.

Animals
-------

Six weeks old male Sprague-Dawley rats were maintained at a temperature of 23±3°C, a relative humidity of 55± 15%, a ventilation frequency of 10\~20 times/h, and with 12 h of light (8:00 am to 8:00 pm off). Temperature and relative humidity were measured every hour using a computer system, and the frequency of ventilation and illumination was measured periodically. There were no abnormalities that could affect the test results during the experiments. All studies were approved by the Institutional Animal Care and Use Committee of Gyeonggi Bio Research Center (approval no. 2016-10-0011, 2017-05-0005).

Gastric secretions and gastric acidity measurements
---------------------------------------------------

Animals were fasted for 24 h before administration of test substances. Test substances (*C. tricuspidata* 70% ethanol extract or ranitidine) were suspended in 0.5% MC before administration. In the vehicle group, only 5% MC was administered. One hour after oral administration of test substances, animals were anesthetized with isoflurane, and the pylorus was ligated. After 8 h of pyloric ligation, animals were sacrificed with CO~2~ gas and gastric juice was collected from the stomach using a 10-mL syringe. The gastric juice was centrifuged at 3,000 rpm for 10 min, the supernatant removed, and the gastric fluid amount (mL), pH, and acidity were measured. To determine gastric acidity, 1 mL of centrifuged gastric juice was dispensed into a tube and titrated to pH 7.0 with 0.1 N NaOH; the amount of 0.1 N NaOH used in the titration was measured. Total acidity was calculated using the following formula:
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Induction of reflux esophagitis and esophageal lesion measurement
-----------------------------------------------------------------

All animals were fasted for 36 h before test substances were administered. One hour after oral administration of test substance (*C. tricuspidata* 70% ethanol extract or ranitidine), animals were anesthetized with tiletamine/ zolazepam (10 mg/kg; Zoletil 50, Virbac, Carros, France) and 2% xylazine hydrochloride (2 mg/kg, Rumpun, Byer Co., Seoul, Korea). The abdomen of the anesthetized rats was shaved and disinfected with povidone, followed by incision along the midline at 4 to 5 cm. The exposed pylorus and the limiting ridge were ligated with silk (3-0, B. Braun Surgical S.A., Barcelona, Spain). The peritoneum was closed with 3/0 absorbable suture (3/0 Surgisorb, Samyang, Seoul, Korea), and the skin was ligated with silk (3-0, B. Braun Surgical S.A.). Eight hours following the operations, animals were sacrificed with CO~2~ gas, and the stomachs and esophagi were collected. Stomachs and esophagi were cut longitudinally using surgical scissors, and the blood was washed with phosphate buffered saline. The dissected stomachs and esophagi were spread on clean paper and photographed with a digital camera (Coolpix P5100, Nikon, Tokyo, Japan) under 200 to 300 lux illumination at the designated site. The distance between the camera and the specimen was measured with object markers and scale bars (mm unit) at the time of photographing. The lesion area of injured esophagus mucosa was measured using Image J (Wayne Rasband; National Institutes of Health, Bethesada, MD, USA).

Cell culture
------------

The U937 cell line (American Type Culture Collection, Rockville, MD, USA) was suspended in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum and 1% calcium phosphate buffer at 37°C.

Measurement of intra-cellular cAMP
----------------------------------

U937 cells were cultured in RPMI-1640 medium, centrifuged at 200 *g*, and suspended in RPMI-1640 medium containing 10 μM RO-20-1724 (Sigma, St. Louis, MO, USA). Cell suspensions were pretreated with *C. tricuspidata* extracts or 10 μM of ranitidine hydrochloride (Sigma) for 5 min and then treated with 10 μM of H~2~R specific agonist dimaprit (Sigma) for 20 min. After 20 min of dimaprit treatment, U937 cells recovered by centrifugation (1,800 *g*) were treated with cAMP assay cell lysis buffer (R&D Systems, Minneapolis, MN, USA) and immediately frozen. The frozen cells were disrupted by repeatedly freezing and thawing three times, centrifuged at 2,000 *g* for 15 min, and cAMP production was measured in the supernatant. The cAMP assay was performed using a cAMP assay kit from R&D Systems.

Statistical analysis
--------------------

Experimental results were expressed as mean±standard error (SE) and analysed using SPSS (version 20, IBM SPSS Corp., Armonk, NY, USA). Levene's test was performed to compare the variance homogeneity for all data. Oneway ANOVA with Tukey's post hoc mean separation tests was used to analyze significance when the variance was homogeneous.

RESULTS
=======

Effect of *C. tricuspidata* on gastric acid secretion
-----------------------------------------------------

The pylori-ligated rat model ([@b24-pnfs-24-159]) was used to investigate the effects of *C. tricuspidata* extracts on total gastric volume and total acidity of gastric juice. Analysis of gastric contents showed that *C. tricuspidata* extracts decreased the amount and total acidity of gastric juices in a concentration-dependent manner. Specifically, 20 mg/kg of *C. tricuspidata* extract showed an inhibitory effect on gastric acid secretion almost comparable to the H~2~R inhibitor ranitidine ([Fig. 1](#f1-pnfs-24-159){ref-type="fig"}). The *C. tricuspidata* ethanol extract decreased gastric acid secretion following pylorus ligature, indicating that this may be the mechanism by which *C. tricuspidata* extracts protect the esophagus mucosa.

Effect of *C. tricuspidata* on reflux esophagitis
-------------------------------------------------

In the vehicle group, most of the esophageal mucosa were damaged by stomach acid, resulting in severe redness. In contrast, rats treated with ranitidine and *C. tricuspidata* extracts showed a decrease in redness due to gastric acid secretion ([Fig. 2A](#f2-pnfs-24-159){ref-type="fig"}). The esophageal injury ratio of the vehicle group was 57.72±5.16%. *C. tricuspidata* extracts at concentrations of 20 and 50 mg/kg attenuated the esophageal injury ratio to 29.41±7.84% and 25.18±7.57%, respectively. Ranitidine at 7.7 mg/kg also attenuated the lesion score to 29.90±6.3% ([Fig. 2B](#f2-pnfs-24-159){ref-type="fig"}, [Table 1](#t1-pnfs-24-159){ref-type="table"}). The *C. tricuspidata* extract-treated group did not show dose-dependent inhibition of esophageal mucosal damage, but the mean level of damage was comparable to that of the ranitidine-treated group. The high-dose *C. tricuspidata* extract-treated group (50 mg/kg) showed the greatest reduction of esophageal mucosal damage.

*C. tricuspidata* inhibits H2R-mediated cAMP production in U937 cells
---------------------------------------------------------------------

H~2~R is a major target of anti-ulcer drugs ([@b15-pnfs-24-159]). Inhibitory effects of H~2~R blockers on gastric acid secretion have been demonstrated in many animal model systems ([@b14-pnfs-24-159]; [@b19-pnfs-24-159]; [@b9-pnfs-24-159]). H~2~R is expressed in immune cells, such as the U937 cell line, which is widely used as a model system for H~2~R activation and GI tract cells ([@b9-pnfs-24-159]; [@b8-pnfs-24-159]; [@b2-pnfs-24-159]). Therefore, we investigated whether *C. tricuspidata* extracts inhibited cAMP production by dimaprit, a selective H~2~R agonist, in U937 cells. Treatment of U937 cells with dimaprit resulted in a significant increase in cAMP, which was inhibited by *C. tricuspidata* extract in a dose-dependent manner ([Fig. 3A](#f3-pnfs-24-159){ref-type="fig"}).

In the above animal experiments, we found that the *C. tricuspidata* 70% ethanol extract effectively inhibited gastric acid secretion and reflux esophagitis. Therefore, we investigated the effects of various concentrations of *C. tricuspidata* ethanol extractions on H~2~R inhibition. Higher ethanol concentration induced greater H~2~R inhibition. The 0% ethanol extract (hot water extract) did not affect H~2~R inhibition ([Fig. 3B](#f3-pnfs-24-159){ref-type="fig"}). Ranitidine, a H~2~R-specific antagonist, almost completely inhibited cAMP production by H~2~R at a concentration of 10 μM ([Fig. 3B](#f3-pnfs-24-159){ref-type="fig"}). When ethanol was used as the solvent at concentrations over 70%, only a very small amount of extract was obtained.

There was no cellular damage in U937 cells treated with ranitidine or *C. tricuspidata* extracts (data not shown), suggesting that the inhibitory effects of H~2~R by *C. tricuspidata* extracts was not due to inducing cell death. We also measured the H~2~R inhibitory effect of *C. tricuspidata* fruit and stem extracts; the fruit extract did not inhibit H~2~R, and the stem extract only showed a small inhibitory effect (data not shown).

DISCUSSION
==========

*C. tricuspidata* has long been used for treatment of gastrointestinal diseases in folk medicine. Although many studies have reported the effects of *C. tricuspidata* on allergy, inflammation, diabetes, and obesity ([@b10-pnfs-24-159]; [@b6-pnfs-24-159]; [@b17-pnfs-24-159]; [@b11-pnfs-24-159]; [@b7-pnfs-24-159]; [@b28-pnfs-24-159]), the mechanism of action is unclear for gastrointestinal diseases such as gastritis and reflux esophagitis. In this study, we suggest that *C. tricuspidata* ethanol extracts may block H~2~R and prevent gastric hyperacidity and reflux esophagitis.

A single oral administration of *C. tricuspidata* ethanol extract reduced gastric acid secretion in pyloric-ligated animals, similar to the effects of ranitidine ([Fig. 1](#f1-pnfs-24-159){ref-type="fig"}), and effectively suppressed esophageal damage in the reflux esophagitis model ([Fig. 2](#f2-pnfs-24-159){ref-type="fig"}). These results suggest that *C. tricuspidata* ethanol extracts inhibit signals related to gastric acid secretion. Thus, we determined whether *C. tricuspidata* inhibits H~2~R-mediated cAMP production in U937 cells. We found that the ethanol extract of *C. tricuspidata* inhibited H~2~R activity in a concentration-dependent manner ([Fig. 3A](#f3-pnfs-24-159){ref-type="fig"}). Inhibition of cAMP signaling by *C. tricuspidata* ethanol extracts was due to blockade of histamine binding to H~2~R, rather than accelerating degradation, based on inhibition observed in the presence of the phosphodiesterase inhibitor RO-20-1724. In addition, when *C. tricuspidata* was extracted with high concentration of ethanol, higher H~2~R inhibitory activity was observed compared with extraction with low concentrations of ethanol or water. These results suggest that the active component of *C. tricuspidata* that inhibits H~2~R is a hydrophobic, and not hydrophilic material. Therefore, we are conducting a follow-up study to identify a single component that specifically inhibits H~2~R in *C. tricuspidata* by fractionating the *C. tricuspidata* extract with hydrophobic solvents such as ethyl acetate.

Antagonism of H~2~R has been the cornerstone of pharmacological treatment of gastrointestinal tract acid disorders, such as gastric hyperplasia and gastritis ([@b15-pnfs-24-159]). Selective H~2~R inhibition and gastric acid secretion by *C. tricuspidata* indicates that *C. tricuspidata* extracts or its active ingredients may be a promising candidate for the treatment of gastric ulcers and other H~2~R-related diseases. Therefore, further studies are needed to demonstrate the effect of *C. tricuspidata* on gastrointestinal dysfunction, such as hypergastric acidity and reflux esophagitis, in humans, and to identify individual *C. tricuspidata* components that inhibit H~2~R.

In conclusion, our data show that *C. tricuspidata* extract can inhibit H~2~R and may effectively prevent diseases such as gastric hyperacidity and reflux esophagitis associated with H~2~R-mediated gastric secretion.
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![Effect of *Cudrania tricuspidata* extract on gastric acid secretion. (A) Total gastric juice secretion after pylorus ligature and (B) total acidity of gastric contents from pylorus-ligated rats. Gastric juice was collected immediately after sacrificing the rats, and the total volume and total acidity of gastric secretions were measured. The pylorus-ligated rats were treated with the indicated dose of *C. tricuspidata* extract. Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 5 mg/kg, 5 mg/kg of *C. tricuspidata* extract; 10 mg/kg, 10 mg/kg of *C. tricuspidata* extract; 15 mg/kg, 15 mg/kg of *C. tricuspidata* extract; 20 mg/kg, 20 mg/kg of *C. tricuspidata* extract. Values are mean±SE. Significantly different from Veh group at \**P* \<0.05 and \*\**P* \<0.01.](pnfs-24-159f1){#f1-pnfs-24-159}

![Effect of *Cudrania tricuspidata* extract on reflux esophagitis. (A) Esophageal lesions and (B) the area ratio of esophageal injury. The esophagus was collected immediately after rats were sacrificed and was cut in the longitudinal direction from the gastroesophageal junction to the pharynx. The dissected esophagus was laid on paper, and photographic images were captured with an optical digital camera. The pylorus- and forestomach-ligated rats were treated with the indicated dose of *C. tricuspidata* extract. Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 20 mg/kg, 20 mg/kg of *C. tricuspidata* extract; 50 mg/kg, 50 mg/kg of *C. tricuspidata* extract. Values are mean±SE. Significantly different from Veh group at \*\**P* \<0.01.](pnfs-24-159f2){#f2-pnfs-24-159}

![Inhibition of H~2~ histamine receptor (H~2~R)-mediated cyclic adenosine monophosphate (cAMP) production by *Cudrania tricuspidata* extract in U937 cells. (A) *C. tricuspidata* ethanol extracts inhibit cAMP production in a dose-dependent manner. (B) H~2~R inhibitory activity of *C. tricuspidata* extracted with various concentrations of ethanol. U937 cells were pretreated with 10 μM of ranitidine or *C. tricuspidata* extracts for 5 min. Next, cells were stimulated with 10 μM of dimaprit. The control group was treated with the same amount of DMSO instead of ranitidine or *C. tricuspidata* extracts. Values are mean±SE. ^\#\#^*P* \<0.01 indicates a significant difference between the control group and the Dimaprit group. A significant difference between the Dimaprit group and the *C. tricuspidata* extract groups at \**P* \<0.05 and \*\**P* \<0.01.](pnfs-24-159f3){#f3-pnfs-24-159}

###### 

Gross esophageal damage in rats with reflux esophagitis

  Groups   Total area (mm^2^)   Lesion area (mm^2^)   Injury ratio (%)
  -------- -------------------- --------------------- ----------------------------------------------------------
  G1       448.18±21.71         261.75±30.22          57.72±5.16
  G2       434.04±26.08         136.05±33.67          29.90±6.30[\*\*](#tfn3-pnfs-24-159){ref-type="table-fn"}
  G3       398.89±20.90         116.54±31.23          29.41±7.84[\*\*](#tfn3-pnfs-24-159){ref-type="table-fn"}
  G4       408.04±12.68         106.60±32.60          25.18±7.57[\*\*](#tfn3-pnfs-24-159){ref-type="table-fn"}

Data were expressed as mean±SE.

The results were statistically analyzed by one-way ANOVA.

Significantly different from G1 at *P* \<0.01.

G1, vehicle (0.5 % MC, 10 mL/kg, n=8); G2, ranitidine hydrochloride (7.7 mg/kg, n=8); G3, *C. tricuspidata* extract (20 mg/kg, n=8); G4, *C. tricuspidata* extract (50 mg/kg, n=8).
